Rifampicin demonstrated robust anti-melanogenic effects in B16F10 melanoma cells by targeting multiple signaling pathways involved in melanogenesis, including cAMP/PKA, MAPK, and GSK-3β/β-catenin pathways. Here, GSK3B is linked to melanoma.